Related Experiment Video
Updated: Sep 14, 2025

A High-throughput Platform for the Screening of Salmonella spp./Shigella spp.
Published on: November 7, 2018
Travellers' diarrhoea - solidifying our knowledgebase
Thomas H A Samuels1,2, Clare E Warrell1,3
1Hospital for Tropical Diseases, University College London Hospitals NHS Foundation Trust.
Purpose Of Review:
Travellers' diarrhoea remains one of the most common diseases amongst international travellers. However, significant uncertainty remains about the most effective strategies for its prevention and management. This review summarises recent advances in travellers' diarrhoea epidemiology, diagnostics, and management, focusing on new severity definitions, the impact of molecular diagnostics, antimicrobial resistance, and postinfectious sequelae.
Recent Findings:
The incidence of travellers' diarrhoea remains substantial although much of this is attributable to mild disease. Viral travellers' diarrhoea is more frequently recognised due to the improved sensitivity of molecular diagnostics. Advances in microbiome research reveal both acute and persistent disruption to the microbiota following travellers' diarrhoea and antibiotic use. New severity definitions incorporating functional impairment offer improved clinical relevance but consensus over use remains lacking. Nonabsorptive antibiotics and probiotics show promise for treatment and prevention, but antimicrobial resistance continues to rise. Postinfectious irritable bowel syndrome (IBS) significantly impacts the recovery of some travellers' diarrhoea patients.
Summary:
Consensus on severity definitions is needed to support successful research into new vaccines and therapeutics. Surveillance of resistance, research into microbiome disruption and recovery, and development of vaccines and probiotics are key priorities. Better pathophysiological understanding and new intervention strategies are required to help alleviate the suffering of post-travellers' diarrhoea IBS.
More Related Videos
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
08:23Culture Methods to Determine the Limit of Detection and Survival in Transport Media of Campylobacter Jejuni in Human Fecal Specimens
Published on: March 10, 2020
Related Concept Videos
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Fungal Phylum Microsporidia
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Bacterial Flora of the Large Intestine
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
Infection
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...